Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec;32(6):727-34.
doi: 10.1055/s-0031-1295720. Epub 2011 Dec 13.

Pulmonary cryptococcosis

Affiliations
Review

Pulmonary cryptococcosis

Kyle D Brizendine et al. Semin Respir Crit Care Med. 2011 Dec.

Abstract

Cryptococcosis is an invasive fungal infection (IFI), caused predominantly by Cryptococcus neoformans or Cryptococcus gattii, that affects both immunocompromised (IC) and non-IC patients. Although the most serious disease manifestation is meningoencephalitis, cryptococcal pneumonia is underdiagnosed and may disseminate to the central nervous system (CNS) and other sites depending upon host defenses and administration of appropriate antifungal therapy. The clinical presentation of pulmonary cryptococcosis varies along a spectrum from asymptomatic infection to severe pneumonia and respiratory failure, and the radiological presentation can be characterized by an array of findings, including nodules, consolidation, cavitary lesions, and a diffuse interstitial pattern. Diagnosis most often relies upon isolation of Cryptococcus from a pulmonary specimen in the appropriate clinical and radiological context. Treatment recommendations include induction therapy with an amphotericin B preparation and flucytosine for IC patients and those with severe disease and fluconazole for mild-to-moderate, localized disease. Knowledge of the pathophysiology, epidemiology, clinical presentation, and treatment of pulmonary cryptococcosis may lead to greater recognition of this underdiagnosed IFI and improved outcomes.

PubMed Disclaimer

Similar articles

  • Cryptococcal lung disease.
    Shirley RM, Baddley JW. Shirley RM, et al. Curr Opin Pulm Med. 2009 May;15(3):254-60. doi: 10.1097/MCP.0b013e328329268d. Curr Opin Pulm Med. 2009. PMID: 19352182 Review.
  • Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.
    Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE. Saag MS, et al. Clin Infect Dis. 2000 Apr;30(4):710-8. doi: 10.1086/313757. Epub 2000 Apr 20. Clin Infect Dis. 2000. PMID: 10770733
  • [Cryptococcosis].
    Yoshida K, Shoji H, Niki Y. Yoshida K, et al. Nihon Rinsho. 2008 Dec;66(12):2350-5. Nihon Rinsho. 2008. PMID: 19069104 Review. Japanese.
  • Cryptococcosis.
    Negroni R. Negroni R. Clin Dermatol. 2012 Nov-Dec;30(6):599-609. doi: 10.1016/j.clindermatol.2012.01.005. Clin Dermatol. 2012. PMID: 23068147 Review.
  • Pulmonary cryptococcosis.
    Jarvis JN, Harrison TS. Jarvis JN, et al. Semin Respir Crit Care Med. 2008 Apr;29(2):141-50. doi: 10.1055/s-2008-1063853. Semin Respir Crit Care Med. 2008. PMID: 18365996 Review.

Cited by

MeSH terms

Substances